News from guardant health A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 06, 2022, 06:16 ET Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent clinical laboratory...

Jul 06, 2022, 06:12 ET Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent clinical laboratory...

Mar 14, 2022, 04:24 ET Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan

The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation...

Mar 14, 2022, 04:22 ET Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan

The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation...

Feb 03, 2021, 05:43 ET Guardant360 CDx submitted for regulatory approval in Japan

Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East & Africa (AMEA) has announced that it has submitted its application to the...

Feb 03, 2021, 05:41 ET Guardant360 CDx submitted for regulatory approval in Japan

Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East & Africa (AMEA) has announced that it has submitted its application to the...

Aug 08, 2020, 08:24 ET Première biopsie liquide à recevoir l'approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le...

Aug 08, 2020, 03:04 ET First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients...

Aug 07, 2020, 15:01 ET First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.

The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients...

Oct 19, 2018, 08:00 ET Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting

New data demonstrating the high sensitivity and specificity of the blood-based Guardant360® and GuardantOMNI™ assays, developed by Guardant Health...

Oct 16, 2018, 08:00 ET Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations

A prospective study in patients with advanced non-small cell lung cancer (NSCLC) has demonstrated that the blood based Guardant360® assay, developed...

Sep 05, 2018, 19:22 ET SLLIP Study Meets Primary Endpoint, Finds the Guardant360 Assay Performs Similar to Standard-of-Care Tissue Testing in Advanced NSCLC, Investigators to Report at WCLC

Researchers will present data at the 19th World Conference on Lung Cancer (WCLC) showing the SLLIP trial met its primary endpoint of demonstrating...

Jul 19, 2018, 11:00 ET New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor...

Jul 12, 2018, 14:00 ET Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications

Guardant Health announced that it has appointed Leena Das-Young, Pharm.D. to serve as General Manager of its LUNAR program. As Guardant Health's...

Jul 12, 2018, 13:51 ET Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer

Guardant Health, Inc. announced that Palmetto GBA, a Medicare Administrative Contractor and leader in evaluating molecular diagnostic technology...

May 23, 2018, 11:30 ET Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications

Guardant Health announced it and its partners will present 29 abstracts at the ASCO Annual Meeting advancing the science of liquid biopsy across...

Apr 26, 2018, 01:00 ET Guardant Health Publishes Extensive Validation of Guardant360® Assay Comprising Largest-Published Blood-Tissue Comparison

The largest published comparison of comprehensive liquid biopsy results to tissue genotyping demonstrated high positive predictive value for the...

Apr 13, 2018, 02:23 ET Guardant Health to Present Validation Data for the GuardantOMNI™ assay

Guardant Health announced it will present data at the American Association for Cancer Research annual meeting detailing the analytical validation of...

Mar 12, 2018, 10:00 ET Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial

The Guardant360® assay, the leading comprehensive liquid biopsy, will be used as the sole liquid biopsy in LC-SCRUM-Japan, a nationwide genomic...

Mar 12, 2018, 10:00 ET Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of GI Cancer Trial

The Guardant360® assay, the leading comprehensive liquid biopsy, will be used to launch a new arm of a nationwide trial run by SCRUM-Japan GI-SCREEN, ...

Feb 15, 2018, 12:18 ET The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDA

The Guardant360® assay, the leading comprehensive liquid biopsy, received an Expedited Access Pathway (EAP) designation from the United States Food...

Nov 16, 2017, 12:05 ET Guardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with Bristol-Myers Squibb

Guardant Health has added Bristol-Myers Squibb Company to the group of pharmaceutical companies it is working with to develop the GuardantOMNI assay, ...

Nov 15, 2017, 14:03 ET New Research Reveals Molecular Heterogeneity of Metastatic Gastroesophageal Cancer

Researchers from the University of Chicago, Dana-Farber Cancer Institute (DFCI), and Guardant Health, Inc. published new evidence of the genomic...

Nov 06, 2017, 10:37 ET Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung Cancer

Research led by scientists at UC San Francisco and the Francis Crick Institute in London has used Guardant Health's database of comprehensive liquid...

Oct 02, 2017, 11:00 ET Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy

Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent ...